Midatech Pharma PLC (LON:MTPH)‘s stock had its “buy” rating reaffirmed by analysts at Panmure Gordon in a research report issued to clients and investors on Friday. They presently have a GBX 380 ($4.96) price objective on the stock. Panmure Gordon’s price target indicates a potential upside of 199.21% from the stock’s current price.
Shares of Midatech Pharma PLC (LON:MTPH) opened at 124.6594 on Friday. The firm’s market cap is GBX 41.81 million. The firm’s 50-day moving average is GBX 145.83 and its 200 day moving average is GBX 141.36. Midatech Pharma PLC has a 52 week low of GBX 100.51 and a 52 week high of GBX 285.00.
About Midatech Pharma PLC
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.